NEUP
Neuphoria Therapeutics
$3.85
+$0.21 (+5.77%)Jul 27, 2026
Key metrics
The numbers that frame NEUP today
- Market cap
- $20.81M
- P/E (TTM)
- -1.7
- EV / FCF
- -0.6
- Gross margin
- 100%
- EV / Sales
- -730.4
- ROIC
- 815.7%
- Div yield
- 0%
- Debt / equity
- 0.0
- 52wk Low
- $3.19
- 52wk High
- $21.40
Growth
Revenue and earnings trend for NEUP
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about NEUP
Is Neuphoria Therapeutics a good buy?
No. Neuphoria Therapeutics has poor quality and weak momentum. Both signals point to a weaker setup. Growth looks weak. That could put pressure on the long-term business case. We think Neuphoria Therapeutics is selling at a very high price.
What is the market capitalization of NEUP?
Neuphoria Therapeutics's market capitalization is $20.81M.
What is the P/E ratio for NEUP stock?
Neuphoria Therapeutics's current P/E ratio is -1.7.
What is the 52-week high for NEUP stock?
The 52-week high for Neuphoria Therapeutics is $21.40. The current close of $3.85 is 82% below that high.
What is the 52-week low for NEUP stock?
The 52-week low for Neuphoria Therapeutics is $3.19. The current close of $3.85 is 20.7% above that low.
Does NEUP stock pay dividends?
Neuphoria Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for NEUP?
Neuphoria Therapeutics's Debt / Equity ratio is 0.